Skip to main content
NewslettersWatchlist

Novo Nordisk A/S ADR(NVO-N)
NYSE

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low121.79
Day High124.25
Open:123.07
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Motley Fool
Novo Nordisk and Ginkgo Bioworks Are Teaming Up. Here's Why That's Bullish for Both Stocks.
Motley Fool
Better Buy: Bristol Myers Squibb or the Vanguard S&P 500 ETF?
Motley Fool
Better Growth Play: Merck or The Vanguard Growth Index Fund?
Barchart
3 Best Mega-Cap Stocks for Dividend Investors
Motley Fool
2 Healthcare Stocks to Buy Hand Over Fist in April
Motley Fool
Novo Nordisk's Stock Could Get Another Boost, Thanks to This Huge Development
Barchart
This Small-Cap Biotech Could Gain Over 165%, Says Wall Street
Motley Fool
Viking Therapeutics Is Great. Here's Why You Shouldn't Buy It.
Barchart
1 Future Dividend Aristocrat to Buy Now
Barchart
Down 32% in a Year, Should Investors Buy the Dip in Pfizer Stock?
Motley Fool
After Wegovy's Approval to Treat Heart Disease, Novo Nordisk Continues to Make Moves
Motley Fool
Could This 1 Detail Help Viking Therapeutics Top Eli Lilly and Novo Nordisk in the Weight Loss Drug Market?
Motley Fool
Why Eli Lilly Stock Topped the Market Today
Motley Fool
Could Viking Therapeutics Stock Be a Millionaire Maker?
Motley Fool
Is It Too Late to Buy Eli Lilly Stock?
Motley Fool
Meet The "Magnificent Seven" of Healthcare Stocks
Motley Fool
Is Novo Nordisk the Best Healthcare Stock for You?
Motley Fool
Diversifying Into This Key Market Is 1 More Reason to Buy Novo Nordisk Stock
Motley Fool
Prediction: This Will Be the Next "Magnificent Seven" Stock
Motley Fool
Novo Nordisk and Nvidia Just Partnered on AI. Is the Stock a Buy?
GlobeNewswire
Appointment of Ms Karen O’Neill as Director
GlobeNewswire
Upgraded Nunyerry North Drill Results Deliver High-Grade Intercepts Up to 6.12 g/t Au
Barchart
Up 68% in 1 Year, Is Novo Nordisk Stock Still a Buy?
Motley Fool
Best Obesity Drug Stock: Eli Lilly, Novo Nordisk, or Viking Therapeutics?
Motley Fool
Uncovering Hidden Gems: 1 AI-Powered Healthcare Stock Set to Dominate the Market
Baystreet
Novo Nordisk Buys Cardior Pharma For $1.1 Billion
Motley Fool
Novo Nordisk and Eli Lilly May Finally Have Some Real Competition
Motley Fool
Is Viking Therapeutics Stock a Millionaire Maker?
Motley Fool
With Shares Trading Near All-Time Highs, Is Now the Time to Take Profits in Novo Nordisk?
Motley Fool
Did Eli Lilly Just One-Up Novo Nordisk?
Motley Fool
Novo Nordisk's New Weight Loss Drug Could Be Better Than Ozempic and Wegovy
Motley Fool
Will Novo Nordisk Overtake Eli Lilly as the Most Valuable Healthcare Stock?

Profile

Bagsv'rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care and Biopharmaceuticals. While the Diabetes and obesity care segment covers insulins, glucagon-like peptide 1 (GLP-1), other protein-related products, obesity and oral anti-diabetic drugs, the Biopharmaceuticals segment includes hemophilia, growth hormone therapy and hormone replacement therapy.Novo Nordisk's most well-known drugs include Levemir, NovoRapid, Victoza, Ozempic, NovoMix, NovoSeven, NovoThirteen, Ryzodeg, Xultophy, Saxenda, Rybelsus, Esperoct, Sogroya and Norditropin, among several others. The company launched its first product for weight management, Saxenda, in the United States in 2015.In August 2018, Novo Nordisk announced that it has acquired all of the shares of Ziylo Ltd.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.